The web Browser you are currently using is unsupported, and some features of this site may not work as intended. Please update to a modern browser such as Chrome, Firefox or Edge to experience all features Michigan.gov has to offer.
Gov. Whitmer Announces IONETIX Corporation $25.75M Investment in Greater Lansing, Creating 53 New Jobs
June 03, 2025
FOR IMMEDIATE RELEASE
June 3, 2025
Contact: press@michigan.gov
Gov. Whitmer Announces IONETIX Corporation $25.75M Investment in Greater Lansing, Creating 53 New Jobs
LANSING, Mich. – Today, Governor Gretchen Whitmer announced IONETIX Corporation is investing $25,750,000 in the Lansing region and creating 53 new jobs. IONETIX Corporation provides cutting-edge diagnostics and therapeutics, specializing in the production and distribution of radiopharmaceuticals and targeted alpha therapy agents for diagnostic imaging and cancer treatment.
“Today’s $25 million investment in Lansing will create 53 good-paying jobs and build on Michigan’s leadership in the biotech and life sciences industries,” said Governor Whitmer. “IONETIX Corporation is betting on Michigan and doubling down on their established presence in Lansing. They know that here in Michigan, we work together to help businesses invest and grow in Michigan so every Michigander can find a good job in their hometown. Let’s keep winning projects in cutting-edge industries and bolster our economic development tools so we can keep growing our economy.”
"We are thrilled with the company’s commitment to Michigan and the Lansing community by investing over $25 million to accelerate the efforts to one day cure cancer,” said Matt McCauley, Senior Vice President for Regional Development at the MEDC. "Team Michigan welcomes IONETIX Corporation’s expansion, furthering Michigan’s leadership in the life sciences and medical technology industries. We applaud the company’s vision to Make it in Michigan."
The company has announced their commitment to renovations, improvements and expansion at their existing Lansing-area facilities where they currently have operations. The expansion investment will help the company increase their supply chain distribution of effective radiopharmaceutical products, accelerating the global effort to cure cancer.
The new jobs created with this expansion project will have starting wages of $25 per hour plus benefits, above the regional median wage of $23.68 per hour. This expansion has received support through the MEDC through a Michigan Business Development Program performance-based grant in the amount of $750,000.
"Delta Township and the Lansing region offer the ideal environment for IONETIX’s continued growth. The area’s highly skilled workforce, robust infrastructure, and strong spirit of public-private collaboration make it the perfect location for our expansion,” said Kevin J. Cameron, Chief Executive Officer of IONETIX. “We are honored to invest in this community and proud that it is the in the forefront of creating diagnostic and therapeutic innovations.”
Expanding the production of these isotopes in Lansing will strengthen Michigan-based academic research and drive new local growth in the biotech and life sciences industries, particularly in drug discovery and development. This investment will also attract companies to conduct clinical trials in Michigan, giving patients access to new cutting-edge cancer treatments.
“IONETIX’s investment demonstrates Michigan’s emerging leadership in the high-growth radiopharmaceutical and nuclear medicine sectors,” said Bob Trezise, president and CEO of the Lansing Economic Area Partnership (LEAP). “This expansion is not only creating high-wage, future-forward jobs—it’s solidifying Michigan’s position as a hub for advanced biomedical research, innovation, and manufacturing. We’re proud to partner with IONETIX, the MEDC and Delta Township to support this transformative project with global impact.”
In addition to MSF support, LEAP has put forward a tailored suite of support that includes funding from the Michigan New Jobs Training Program as well as a Michigan Works! proposal for training and workforce support.
Michigan is a hub of innovation and commercialization in the life sciences and medtech industries. With leading pharmaceutical and world-class medtech companies, the Great Lakes State is a prime location for innovative jobs, a high quality of life, and lower cost of living.
With their expansion, the company is positioned to leverage Michigan’s research expertise and highly ranked degree programs in medicine, biological science and other disciplines to help train, retrain and attract talent to drive the next generation of industry innovation forward.
For those interested in pursuing a career with IONETIX, please click <HERE.>
###
Author: